Infanrix vaccine market seen growing on higher birth rates and pertussis cases

The Business Research Company says the global Infanrix and Infanrix-hexa market is set for steady expansion through 2035, driven by rising pediatric vaccine demand, broader immunization coverage and higher healthcare spending. North America led the market in 2025, while Asia-Pacific is expected to grow faster as birth rates and vaccination programs expand.

Why it matters: - Infanrix and Infanrix-hexa are pediatric vaccines used to protect children against multiple serious infectious diseases. - The market matters because combination vaccines can reduce the number of shots children need while supporting broader immunization coverage. - Demand is rising as governments, health systems and global health groups expand vaccination programs.

What happened: - The Business Research Company released its Infanrix and Infanrix-hexa Global Market Report 2026 – Market Size, Trends, and Forecast 2026-2035. - The report says the market will grow as routine immunization programs broaden and public health infrastructure improves. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow faster in the coming years. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also added market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis in its 2026 reports.

The details: - Infanrix protects infants and young children against diphtheria, tetanus and pertussis. - Infanrix is typically given in multiple doses starting at 2 months of age. - Infanrix-hexa protects against six diseases: diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b, or Hib. - The report points to rising birth rates in developing countries as a major growth driver. - Wider universal immunization coverage is another expected catalyst. - More investment in vaccine production capacity is expected to support supply. - Greater use of combination vaccines is expected to remain a key trend because it reduces the number of doses. - Cold chain logistics improvements, expanded national vaccination programs and stronger vaccine-safety compliance are also cited as trends. - Rising pertussis cases are boosting demand for these vaccines. - Ireland’s Health Protection Surveillance Centre reported about 514 pertussis cases in 2024, up from 18 in 2023. - Higher healthcare spending is also supporting the market. - OECD member-country average health spending per capita was nearly $6,000 in May 2024, with the United States at the top of the list. - Child mortality trends add to the case for vaccination. - UNICEF reported in March 2025 that 4.8 million children under age 5 died in 2023, or about 13,100 deaths a day. - The report includes a free sample and a full report available online: Download a free sample and View the full market report.

Between the lines: - The report frames the market as a public-health story as much as a commercial one. - Higher pertussis incidence, especially where vaccination gaps remain, strengthens the case for combination pediatric vaccines. - The regional split suggests mature markets are leading on current size, while developing markets are set to drive incremental growth. - The emphasis on dose reduction, logistics and regulatory compliance points to execution as a key competitive factor, not just demand.

What's next: - The market is expected to keep expanding through 2035 if immunization coverage continues to widen and birth rates remain elevated in developing economies. - Faster growth in Asia-Pacific will likely depend on national vaccination rollouts, access to production capacity and stronger supply chains. - Ongoing monitoring of pertussis outbreaks and child mortality trends will remain important for vaccine demand.**